Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors
Randy F Sweis, Georgina V Long, Adil Daud, et al.
Oncogene
|
January 31, 2018
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma
Dima Ghannam-Shahbari, Eyal Jacob, Reli Rachel Kakun, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 9, 2021
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
Byoung Chul Cho, Kiyotaka Yoh, Ruth Perets, et al.
Cell Reports
|
January 16, 2020
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
Eleni Maniati, Chiara Berlato, Ganga Gopinathan, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Cell
|
December 17, 2013
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models
Ruth Perets, Gregory A Wyant, Katherine W Muto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
Kevin J Harrington, Stephane Champiat, Joshua D Brody, et al.
Nature
|
May 3, 2019
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
Mark A Eckert, Fabian Coscia, Agnieszka Chryplewicz, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors
Randy F Sweis, Georgina V Long, Adil Daud, et al.
Oncogene
|
January 31, 2018
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma
Dima Ghannam-Shahbari, Eyal Jacob, Reli Rachel Kakun, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Investigational New Drugs
|
April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 9, 2021
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
Byoung Chul Cho, Kiyotaka Yoh, Ruth Perets, et al.
Cell Reports
|
January 16, 2020
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
Eleni Maniati, Chiara Berlato, Ganga Gopinathan, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Cell
|
December 17, 2013
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models
Ruth Perets, Gregory A Wyant, Katherine W Muto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
Kevin J Harrington, Stephane Champiat, Joshua D Brody, et al.
Nature
|
May 3, 2019
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
Mark A Eckert, Fabian Coscia, Agnieszka Chryplewicz, et al.
Page
of 4